Isakov V, et al. - Experts conducted the TURQUOISE-IV trial to test the treatment regimen that involved administration of ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin in chronic hepatitis C virus genotype 1b-infected cirrhotics. Given that in TURQUOISE-II/-III trials, 12-week sustained virologic response (SVR) rates of 100% were seen with the direct-acting antiviral agents ombitasvir (OBV), paritaprevir (PTV), ritonavir, and dasabuvir (DSV) in GT1b-infected patients. At 12 weeks after 12 weeks’ treatment with OBV/PTV/ritonavir+DSV+RBV, SVR was achieved by 100% Russian and Belarusian patients with hepatitis C GT1b infection and compensated cirrhosis. Findings suggested a good tolerability of the treatment.